Resveratrol-Mg hydroxide complex display enhanced bioavailability: A possible application in DM-1 disease

Scientific evidence and clinical studies have extended the knowledge of the use of resveratrol for the treatment of different human pathologies and metabolic disorders. Effects on human health are limited by the low bioavailability of resveratrol, because it has low solubility in water despite high membrane permeability. Based on biopharmaceutical classification system, bioavailability of resveratrol is limited by the dissolution rate. A new natural resveratrol form supported by magnesium hydroxide (Resveratrol-Mg complex, trademarked Revifast), has been developed with improved dissolution rate and the mechanism was investigated. Pharmacokinetic profiles were carried out on New ZealandWhite hybrid breeds after oral administration dose of 50 mg/kg resveratrol suspension obtained by Polygonum cuspidatum (98% resveratrol weight content) or Resveratrol-Mg complex. The mean plasma resveratrol concentration in animals treated with Resveratrol-Mg complex, is statistically greater than the other form. In vitro evidence suggest that resveratrol promote electrophysiological shift of L-type calcium current in myoblast C2C12 model. Possible clinical application of Resveratrol-Mg complex on dystrophy miotonic type I disease was discussed.